MedinCell announces the start of a Phase 3 study in the United States on the second long-acting injectable antipsychotic to use MedinCell's technology (mdc-TJK program).

The aim is to evaluate the efficacy and safety of what could be the first subcutaneous formulation of long-acting olanzapine injection (LAI) for the treatment of schizophrenic patients.

The first patients are expected to be enrolled in the coming days.


Copyright (c) 2023 CercleFinance.com. All rights reserved.